The Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) is a G-protein-coupled receptor whose function in vivo has been incompletely characterized. One of the reasons is that its current known ligands, prostaglandin D 2 (PGD 2 ) and some of its metabolites, have either poor selectivity for CRTH2 or are metabolically unstable in vivo. In this study, we describe the biological and pharmacological properties of L-888,607, the first synthetic potent and selective CRTH2 agonist. We show that L-888,607 exhibits: 1) sub-nanomolar affinity for the human CRTH2 receptor, 2) high selectivity over all other prostanoid receptors and other receptors tested, 3) agonistic activity on recombinant and endogenously expressed CRTH2 receptor, and 4) relative stability in vivo. L-888,607 thus represents a suitable tool to investigate the in vivo function of CRTH2.
Introduction

CRTH2 (Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells) is a G-protein-coupled receptor closely related to chemoattractant receptors
for the N-formyl peptide, the complement peptides C3a and C5a and the leukotriene LTB4. It was first reported to be selectively expressed on human T-helper type 2 cells (Nagata et al., 1999b) . It is also expressed on T-cytotoxic type 2 cells, eosinophils and basophils (Nagata et al., 1999a; Cosmi et al., 2000; Sawyer et al., 2002) . CRTH2 mRNA is found in various adult tissues in the digestive tract, heart, thymus, spleen and brain (Sawyer et al., 2002) . The roles played by this receptor throughout the body are currently unknown. However, it has been demonstrated that its activation by prostaglandin D 2 (PGD 2 ) can increase eosinophil, basophil and Th2 cell motility (Gervais et al., 2001; Hirai et al., 2001; Monneret et al., 2001) . Activation of CRTH2 has also been shown to modulate eosinophil morphology and degranulation (Gervais et al., 2001) , basophil degranulation (Gervais et al., 2001; Yoshimura-Uchiyama et al., 2004) and Th2 cell cytokines secretion (Tanaka et al., 2004) . The currently known high affinity ligands for CRTH2 are the agonists PGD 2 , some PGD 2 metabolites (DK-PGD 2 ), 15-deoxy-∆ 12,14 -PGJ 2 , PGJ 2 , and ∆ 12 -PGJ 2 ) (Sawyer et al., 2002) , and indomethacin (Hirai et al., 2002) and the antagonist ramatroban (Sugimoto et al., 2003) .
PGD 2 is an arachidonic acid metabolite implicated in a wide range of physiological events including sleep induction, goblet cell depletion, vasodilation, increased microvascular permeability, eosinophil infiltration, smooth muscle relaxation, contraction of the myometrium, inhibition of platelet aggregation, cell survival, control of intraocular pressure and allergic responses (Nagata and Hirai, 2003) . PGD 2 binds with equivalent This article has not been copyedited and formatted. The final version may differ from this version. affinity to DP and with lower affinities to FP and EP 3 , all members of the prostanoid receptor family. Because of the non-selectivity of PGD 2 and its instability in vivo, it has been difficult to determine which receptor is responsible for each effect mediated by PGD 2 (Robinson et al., 1989; Liston and Roberts, 1985) . The discovery of BW245C, a selective and stable synthetic agonist of DP has allowed the identification of DP-specific effects mediated by PGD 2 such as vasodilation, relaxation of smooth muscle and platelet aggregation (Whittle et al., 1983; Wright et al., 1998) . However, a number of PGD 2 functions could not be mimicked by BW245C including increased microvascular permeability, eosinophil infiltration, and goblet cell depletion (Woodward et al., 1990; Fernandes and Crankshaw, 1995) . To investigate whether these functions are mediated through the CRTH2, investigators have used the selective agonist DK-PGD 2 , a metabolic product of PGD 2 . Unfortunately, given the inherent metabolic instability of PGD 2 and some of its metabolic intermediates, one must interpret functional data with caution. Therefore, given that PGD 2 and potentially DK-PGD 2 can be metabolized and that some intermediates may serve as activators of receptors other than the CRTH2 (Bocher et al., 2002) , a synthetic, stable CRTH2 ligand is needed to investigate the role of this receptor in vivo.
Here, we describe the biological and pharmacological properties of L-888,607, the first synthetic, potent and selective CRTH2 agonist.
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Materials and methods
Chemicals.
L
acetic acid), and compound H ({9-[(4-chlorophenyl)thio]-6-cyano-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl] acetic acid) are racemic compounds that were synthesized at Merck-Frosst (Montreal, Canada). The two enantiomers L-888,607 and L-888,291 (Sand R-enantiomers, respectively) were isolated from L-883,595. PGD 2 , 13-14-dihydro-15-keto-PGD 2 (DK-PGD 2 ), and BW-245C were purchased from Cayman Chemical.
Radioligand binding assay
Prostanoid receptor binding assays were performed at room temperature in a final volume of 0.2 ml in 10 mM HEPES/KOH pH 7.4 (CRTH2, DP and IP) or 10 mM MES/KOH pH 6.0 (EP subtypes, FP and TP), containing 1 mM EDTA and 10 mM MnCl 2 (CRTH2) or 10 mM MnCl 2 only (DP, FP, IP and TP) or 1 mM EDTA and 10 mM MgCl 2 (EP subtypes) This article has not been copyedited and formatted. The final version may differ from this version. µg for EP2, 2 µg for EP3, 10 µg for EP4, TP and IP, 60 µg for FP). Incubations were conducted for 60 minutes at room temperature and terminated by rapid filtration through a 96-well Unifilter GF/C (Packard) using a Tomtec MachIII semi-automated harvester.
The filters were then washed with 4 ml of the same buffer and residual radioligand bound to the filter was determined by liquid scintillation counting following equilibration in 50
µl Ultima Gold F TM (Unifilter) (Packard) using a 1450 MicroBeta (Wallac).
i [cAMP] measurements
The intracellular concentration of cAMP was determined using the [ 125 I]-cAMP scintillation proximity assay (Amersham) as previously described (Sawyer et al., 2002) . 
Eosinophil purification
Circulating eosinophils were isolated from heparinized venous blood from healthy volunteers as previously described (Gervais et al., 2001) . Briefly, erythrocytes were removed by addition of Dextran-T500 (Pharmacia) and mononuclear cells were removed by means of centrifugation over Ficoll-Paque (Pharmacia). Remaining erythrocytes were lysed by brief incubation in water and the eosinophils were isolated from the granulocyte fraction by negative depletion using immunomagnetic beads directed against CD16
(Miltenyi Biotec). The purity of the eosinophil fraction was evaluated by flow cytometry on a CELL-DYN 3700 System (Abbott Laboratories) on the basis of size, granularity and lobularity. In general, the populations were composed of over 90-95% eosinophils with 5-10% contaminating neutrophils and lymphocytes.
Immunofluorescence Microscopy
Purified eosinophils were resuspended in RPMI-1640 media supplemented with 0.5% (v Fluorescence Microscope (Zeiss).
Eosinophil chemotaxis
Purified eosinophils were resuspended at 3.0x10 6 cells/ml of RPMI-FBS and 0.1 ml was deposited in the top half of a transwell chamber (6.5-mm Transwell, 3.0 µm polycarbonate membrane from Costar). Test compounds (100 nM of either DK-PGD 2 or L-888,607) or DMSO vehicle were added to 0.6 ml of RPMI-FBS to the bottom chamber to a final vehicle concentration of 0.1% v v -1 . After 30 minute in a CO 2 chamber, the upper chamber was removed and the eosinophils that had migrated to the lower chamber were photographed with a 35 mm SLR camera (Contax) mounted on an Axiovert25 microscope (Zeiss). Individual cells were counted and the mean of two chambers was determined for each test condition. Chemotaxis efficiency is expressed as the number of transmigrating cells with the agent, divided by the number of transmigrating cells in presence of vehicle only (fold-increase over background).
Pharmacokinetic profile of L-888607
Male (ICR)BR mice with an average weight of 42 grams were obtained from Charles River Laboratories. All procedures were approved by the Animal Care Committee at Merck-Frosst Canada.
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Results
Identification of a synthetic human CRTH2 receptor ligand
L-883,595 a racemic compound with some affinity for the human DP receptor (K i = 211 nM) was identified in a screen to have a higher affinity for the human CRTH2 (K i = 4 nM) (see structure in figure 1 ). The affinity values were determined by equilibrium competition analysis using 
L-888,607 is a highly selective ligand for CRTH2
The affinity of L-888,607 for all the other recombinant human prostanoid receptors was evaluated by equilibrium competition analysis (Table 1 ). This analysis revealed that L-888,607 displays a relatively high selectivity for CRTH2 with an affinity 363-fold lower for the TP receptor and more than 1000-fold lower for all the other prostanoid receptors. The rank order of affinity is CRTH2 >> TP > EP3 > DP > EP4 > EP2 > FP > IP > EP1. No significant binding was observed at a concentration up to 10 µM on various chemokine receptors (CCR1, CCR2, CCR4, CCR5, CXCR1, CXCR2 and CXCR3) on the anaphylatoxin receptors (C3aR and C5aR) and on the cyclooxygenases (Cox-1 and Cox-2; data not shown).
L-888,607 is a potent agonist at the human recombinant CRTH2 receptor
In a previous study, we reported that recombinant human CRTH2 is coupled to adenylate cyclase via the PTX-sensitive inhibitory trimeric Gαi/o protein in HEK293
This article has not been copyedited and formatted. The final version may differ from this version. (Sawyer et al., 2002) . Substitution of PGD 2 for L-888,607 in this functional assay revealed that this synthetic compound is a full agonist of the hCRTH2 by inhibiting cAMP production with an EC 50 of 0.5 ± 0.3 nM (Figure 2 ).
BW245C, a selective DP agonist, did not inhibit cAMP production in this assay at concentrations up to 1 µM (data not shown).
L-888,607 triggers eosinophil morphological changes
In order to validate L-888,607 as an agonist on endogenous levels of CRTH2, we evaluated its effects on isolated human eosinophils. We have previously shown that eosinophils undergo rapid morphological changes when incubated with CRTH2-receptor agonists like PGD 2 and DK-PGD 2 (Gervais et al., 2001) . Using antibodies directed against actin to better visualize morphological changes of the cells we demonstrated that like PGD 2 and DK-PGD 2 , L-888,607 is capable of inducing a morphological response in freshly isolated and purified human eosinophils (Figure 3 ).
L-888,607 stimulates eosinophil chemotaxis
In order to further confirm that L-888,607 is an agonist on endogenously expressed CRTH2, we evaluated its capacity to stimulate human eosinophil chemotaxis. It was previously reported that PGD 2 and DK-PGD 2 can optimally stimulate eosinophil chemotaxis at a concentration ≥ 100 nM (Hirai et al., 2001; Monneret et al., 2001) . We thus placed freshly isolated and purified human eosinophils in the upper compartment of This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In this study, we describe the first synthetic compound to selectively bind and activate the PGD 2 receptor, CRTH2. We showed that L-888,607 exhibits: 1) subnanomolar affinity for the human CRTH2 receptor, 2) high selectivity over all other prostanoid receptors and some other chemokine and anaphylatoxin receptors, 3) agonistic activity on recombinant and endogenously expressed CRTH2 receptor, and 4) relative stability in vivo. L-888,607 thus represents a suitable tool to investigate the in vivo function of CRTH2.
The fact that the synthetic ligands L-888,607 and BW245C can selectively bind to CRTH2 and DP respectively indicates that while they share the same natural ligand (PGD 2 ), their binding pockets are sufficiently different to enable the design of selective ligands. This is consistent with the fact that CRTH2 shares less sequence similarity to DP and other prostanoid receptors than to receptors for leukotrienes and anaphylatoxins.
Another synthetic compound, indomethacin, has previously been reported to be a potent CRTH2 agonist (Hirai et al., 2002) . However, the use of indomethacin to study the endogenous function of CRTH2 would be complicated by its well established antiinflammatory properties through cyclooxygenases inhibition (Barnett et al., 1994) . Of particular interest is the relative position of the acetic acid side chain compared to the benzoyl group on indomethacin which occupies the same arrangement in space as the acetic acid side chain and the phenyl sulfide group on L-888,607. This later similarity could explain, in part, a shared affinity of both compounds for the CRTH2 receptor.
Interestingly, the CRTH2 antagonist ramatroban is also an indole core molecule which bears an aliphatic carboxylic acid side chain (see figure 1 ; Sugimoto et al., 2003) . In addition, the relative position of the acetic acid side chain could be considered as similar to the side chain position of L-888,607 and indomethacin.
When comparing the L-888,291 and L-888,607 stereoisomers, the stereochemistry at the chiral center bearing the acetic acid group appears to play a central role in determining selectivity toward the CRTH2 and DP receptors. The presence of a carboxylic acid is necessary for potency in both cases. Based on L-888,607's affinity for the CRTH2 receptor, it seems that an R configuration at the chiral center allows the compound to acquire a better conformation to fit the CRTH2 receptor rather than the S configuration, contrary to the DP receptor which prefers the S configuration. We have shown that the pharmacokinetic parameters of L-888,607 are suitable for in vivo investigations. In mice, exposure levels of L-888,607 when administered once intraveinously at 5 mg/kg or orally at 20 mg/kg are well above its affinity at the murine CRTH2 receptor (IC 50 = 18.8 ± 1.7 nM) for a period of at least 8 hours.
In conclusion, we identified L-888,607, a potent, selective and stable CRTH2 agonist that will prove useful in identifying the role of CRTH2 in vivo and together with the selective DP agonist BW245C, can be used to distinguish whether some biological activities associated with PGD 2 are mediated through CRTH2 or DP. This article has not been copyedited and formatted. The final version may differ from this version. 
